EVOKE-01 Trial

[Slide 1] Objective: To identify the nature and frequency of distorted presentation or "spin" (ie, specific reporting strategies, whatever their motive, to highlight that the experimental treatment is beneficial, despite a statistically nonsignificant difference for the primary outcome, or to .. .. ...

[Slide 1] EVOKE-01: Global, Randomized, Open-Label, Phase 3 Study Key eligibility criteria Measurable stage IV NSCLC Sacituzumab End points ECOG PS 0-1 Primary Radiographic progression after platinum- govitecan 10 mg/kg on Days 1 and OS based and anti-PD-(L)1-containing regimenᵃ N = 603 8 of 21-day cycles Secondary In addition, patients with known AGAs R PFS, ORR, DOR, and DCR must have received ≥ 1 approved TKIb 1:1 by INV per RECIST v1.1 EGFR/ALK test required. Testing of other Docetaxel AGAs recommended 75 mg/m2 on Day 1 of Safety and tolerability Previously treated stable brain 21-day cyclesᵈ QoL using NSCLC-SAQ metastases were included Stratified by No prior treatment with Topo-1 inhibitors, Histology (squamous VS nonsquamous) Trop-2-targeted therapies, or docetaxel Response to last anti-PD-(L)1-containing regimen (responsive [best response CR/PR] VS nonresponsive [PD/SD]) Received prior targeted therapy for AGA (yes VS no) At data cutoff (29 November 2023), the study median follow-up was 12.7 months (range, 6.0-24.0) *(Neo)adjuvant therapy counted if progression within 6 months of platinum treatment and while on maintenance with checkpoint elibitor agent. any local approval exists for targeted therapy to that genomic storation Based = bcal SOC and availability of testing/approved targeted agent. Until PD or unacceptable toxicity AGA actionable genomic elteration CR, complete response, DCR disease control rate; DOR, duration of response, ECOG PS, Eastern Cooperative Oncology Group performance status; INV, investigator, NSCLC, non-smal cell lung cancer, NSCLC-SAQ Non-small Cell Lung Cancer Symptom Assessment Questionnaire, ORR objective response rate; OS, overal united PD, progressive disease, PD-(L)1, programmed death (ligand) 1,PFS, progression-free survival, PR partial response; OOL, quality of is R, randomization, RECIST n 1, Response Evaluation Citeria in Solid Tumors version 1.1.SD so stable disease, SOC, standard of care, TKI, tyrosine kinase inhibitor; Topo-1, topoisomerase-1 Trop-2, trophoblest cell surface antigen 2. 2024 ASCO #ASCO24 PRE SENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN security CINCAL ANNUAL MEETING Presentation N property of the author and ASCO Permission required by - carlod ENDWLEDGE CONDUERS CANCER --- [Slide 2] Overall Survival: Subgroup Analyses Subgroup Hazard ratio HR (95% CI) Overall (n = 603) 0.84 (0.68-1.04) Histology Squamous (n = 164) 0.83 (0.56-1.22) Nonsquamous (n = 439) 0.87 (0.68-1.11) Best response to last anti-PD-(L)1-containing regimen PD/SD (n = 383) 0.75 58-0 97) CR/PR (n = 219) 1.09 (0.76-1.58) Received prior therapy for AGA No (n = 559) 0.89 (0.72-1.11) Yes (n = 44) 0.52 (0.22-1.23) Age group 0.80 (0.59-1.08) < 65 years (n = 297) 0.90 (0.68-1.20) ≥ 65 years (n = 306) Baseline ECOG PS 1.06 (0.70-1.60) 0 (n = 190) 0.81 (0.64-1.04) 1 (n = 410) 0.125 0.25 0.5 1 2 4 8 AGA, actionable genomic alteration, Cl, confidence interval, CR, complete response, ECOG PS, Eastern Cooperative Oncology Group performance status, HR, hazard retio, PD, progressive disease, PD-4)1. programmed - (igand) '' PR, partial response, SD, stable disease ASCO i B I 2024 ASCO PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre UNIOL #ASCO24 ENDWLEDGE CONDUERS CANCER - --- [Slide 3] ICARUS ICARUS-Lung01 LUNG Study Design Multi-center, single-arm, phase 2 study (NCT04940325) KEY ELIGIBILITY CRITERIA NSCLC (stage IIIB, IIIC, or IV) Primary Endpoint: ECOG PS of 0 or 1 Investigator-assessed ORR* Progressed on prior 1-3 lines: Dato-DXd 6 mg/kg Q3W Without known mutations: anti PD-1/PDL-1 containing therapy and a platinum-doublet regimen until PD or unacceptable toxicity Secondary Endpoints: With known EGFR, BRAF, MET ALK, ROS1, RET DOR, PFS, CBR, OS NTRK alterations: one line of an approved targeted agent and one platinum-doublet regimen Safety and tolerability Asymptomatic brain metastases Baseline C1D3 EOT Exploratory Endpoints: Mandatory sample collection : Or C2D3 Predictors of response/resistance Tumor biopsy (1 Frozen + 3 FFPE) Dynamics of TROP2 expression Blood (5 to 69 ml) before and after treatment CTCs levels during treatment ECOG PS: Eastern Cooperative Oncology Group Performance Status, FFPE: Formalin-Fixed Paraffin-Embedded, Q3W every 3 weeks, PD: Progressive Disease, C Cycle, D. Day, EOT End of Treatment, ORR: Objective Response Rate, DOR: Duration of Response, CBR: Clinical Benefit Rate, CTCs: Circulating Tumor Cells . Confirmed ORR as per RECIST V1.1 assessment every 6 weeks until objective progressive disease 2024 ASCO PRE SENTED BY: D. Planchard, MD, PhD ASCO AUTHOR exempt CINCAL #ASCO24 ANNUAL MEETING Presentation a property of the ACO and ASCO Permission required for - order DISCOUNT CONDUERS CANCER --- [Slide 4] ORR: overall population and by subgroups ICARUS LUNG 80 Histology Non-Squamous Squamous Overall population, N=100 Confirmed ORR, % 26.0 60 [95%CI] [17.4 : 34.6] 40 DOR, median (months) 7.0 [95%CI] [5.5;11.9] 20 36 Change from baseline (%) CBRᵇ, % 0 [95%CI] [26.6 45.4] -20 ORR by histology (N=100)/genomic alterations (N=85) -40 ORR by NSQ (N=82) SCC (N=18) histology, % 30.5 5.6 -60 [95%CI] [20.8;41,6] [0.14:27.3] ORR by EGFR, Present (N=12) Absent (N=73) -80 BRAF mut, % 50.0 23.2 [95%CI] [21.1;78.9] (14.2;34.7) -100 *11 Patients with EGFR and 1 BRAFV600E alterations HO po <10% is rejected, P value< 0001 Patient KRAS mut (N=11) ORR: 63.6% [30.8; 89.1%] KRAS wt (N=74) ORR: 81.6% [12.9; 32.7%) NSQ: Non-Squamous Cell Carcinoma "Confirmed ORR; clopper-Pearson (Exact) method was used for confidence interval; Defined as the presence of ≥ 1 partial or complete response, or 8 stable disease for >6 months under treatment, 111 EGFR: exon 19, 20, 21; 1 BRAFV600E; KRAS G12C (n=7) ASCO - 2024 ASCO PRE SENTED BY: D. Planchard, MD, PhD GNICK #ASCO24 ENOMLEDGE CONDUERS CANCER ANNUAL MEETING Presentation # property of the author and ASCO Permission required for - contact

[Slide 1] Trial TROPION-Lung01 EVOKE-01 Primary endpoint PFS & OS OS Drugs Datopotomab Deruxtecan Docetaxel Sacituzumab Govitecan Docetaxel No of Patients 299 305 299 304 Median F/U 10.9m 9.6m 12.7m ORR 26.4% 12.8% 13.7% 18.1% DOR 7.1m 5.6m 6.7m 5.8m PFS 4.4m 3.7m 4.1m 3.9m PFS HR 0.75 (0.62-0.91) 0.92 (0.77-1.11) PFS Sq 2.8m 3.9m 3.8m 3.9m PFS Sq HR 1.38 (0.94-2.02) 0.94 (0.67-1.32) PFS NonSq 5.6m 3.7m 4.1m 4.0m PFS NonSq HR 0.63 (0.51-0.78) 0.93 (0.75-1.15) OS 12.4m 11.0m 11.1m 9.8m OS HR 0.90 (0.72-1.13) 0.84 (0.68-1.04) TRAEs ≥G3 25% 41% 52.7% 60.1% Stomatitis, any 54% 20% 13.2 20.1 ILD, any 8% 4% NA NA TRD 2% 0.3% 1.4% 1.0% Payload Deruxtecan (topo-I) NA SN-38 (topo-I) NA DAR 4 NA 7.6 NA Antibody IgG1 NA IgG1 NA Linker Tetrapeptide based cleavable NA Hydrolysable pH sensitive linker NA ClinicalTrial.gov NCT04656652 NCT05089734

[Slide 1] ASCO Abstract LBA8500 2024 ANNUAL MEETING 2024 ASCO Annual Meeting, May 31 - June 4, 2024, Chicago, IL, USA Sacituzumab Govitecan vs Docetaxel in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy and PD-(L)1 Inhibitors: Primary Results From the Phase 3 EVOKE-01 Study Luis G. Paz-Ares, MD, PhD,¹ Oscar Juan-Vidal, MD,2 Giannis S. Mountzios, MD, PhD,³ Enriqueta Felip, MD, PhD,4 Niels Reinmuth, MD,⁵ Filippo de Marinis, MD, PhD,6 Nicolas Girard, MD, PhD,⁷ Vipul M. Patel, MD,8 Takayuki Takahama, MD, PhD,9 Scott P. Owen, MD,¹⁰ Douglas M. Reznick, MD,¹¹ Firas B. Badin, MD,¹² Irfan Cicin, MD,¹³ Sabeen Mekan, MD,14 Riddhi Patel, PharmD,14 Eric Zhang, PhD,¹⁴ Divyadeep Karumanchi, PharmD,14 Marina Chiara Garassino, MD¹⁵ "Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Complutense University and Ciberonce University and Ciberonc, Madrid, Spain; Hospital Universitari Politecnic La Fe de Valencia, Valencia, Spain; PHenry Dunant Hospital Center, Athens, Greece; "Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany, European Institute of Oncology IRCCS, Milan, Italy; Institut du Thorax Curie Montsouris, Institut Curie, Paris, France; Florida Cancer Specialists and Research Institute, Ocala, FL, USA; *Kindai University, Osaka, Japan; "McGill University Health Centre, Montreal, Quebec, Canada; "Rocky Mountain Cancer Center, Aurora, CO, USA; Baptist Health Medical Group, Lexington, KY, USA: Pistinye University, Medical Center, Istanbul, Turkey, "Gilead Sciences, Inc, Foster City, CA, USA; University of Chicago Comprehensive Cancer Center, Chicago, IL, USA 2024 ASCO #ASCO24 PRESENTED IV: Dr. Luis G, Paz-Ares, Hospital Universitario 12 de Octubre ANNUAL MEETING ASCO INCOME I 8 CURRICAL DRICOLOGY Presentation property - and ABCD - - for - - KNOWLEDGE CONQUERS CANCER --- [Slide 2] Primary End Point: Overall Survival (ITT) SG Docetaxel 100 (n = 299) (n = 304) 90 Median, months (95% CI) 11.1 (9.4-12.3) 9.8 (8.1-10.6) 80 HR (95% CI) 0.84 (0.68-1.04) 1-sided P-value 0.0534 70 12-month OS rate, % 46.59 36.72 os probability (%) 60 (95% CI) (40.45-52.50) (30.88-42.57) 1-sided P-value for significance was Ps 0.0223 50 46.6% 40 30 36.7% 20 10 SG Docetaxel 0 0 2 4 6 8 10 12 14 16 18 20 Patients still at risk, N (events) Time (months) SG 299 (0) 275 (23) 234 (63) 212 (83) 175 (112) 140 (137) 76 (150) 40 (162) 17 (166) 10 (167) 0 (168) Docetaxel 304 (0) 277 (23) 234 (65) 201 (98) 158 (131) 128 (151) 64 (178) 41 (184) 15 (187) 7 (187) 2 (187) CI, confidence interval, HR, hazard ratio, ITT, intent-to-treat; OS, overall survival; SG, sacituzumab govitecan. 2024 ASCO #ASCO24 PRESENTED BT: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation a property of the author and ASCO Permission required for reuse, contact cermissions@asco org. KNOWLEDGE CONQUERS CANCER --- [Slide 3] Overall Survival: Best Response to Last Anti-PD-(L)1-Containing Regimen SG had a 3.5-month median os improvement over docetaxel among subgroups with nonresponsive (SD/PD) disease Nonresponsive (SD/PD) Responsive (CR/PR) 100 100 SG Docetaxel SG Docetaxel 90 (n=192) (n=191) 90 (n = 106) (n=113) 80 Median, months 11.8 8.3 80 Median, months 9.6 10.6 (95% CI) (9.6-12.5) 0-10.6) (95% CI) (8.1-14.4) 70 (8.9-12.8) 70 os probability (%) HR (95% CI) 0.75 (0.58-0.97) 50 os probability (%) HR (95% CI) 1.09 (0.76-1.56) 60 60 47.7% 50 44.0% 40 40 41.2% 30 30 34.0% 20 20 SG 10 SG 10 Docetaxel Docetaxel 0 0 0 2 4 6 8 10 12 14 16 18 20 0 2 4 6 8 10 12 14 16 18 20 Patients still at risk, N (events) Time (months) Patients still at risk, N (events) Time (months) SG 192(0) 175(16) 149(41) 135(54) 116(72) (8(84) 53(95) 26(105) 11(107) 8(107) 0(108) SG 106(0) 99(7) 84(22) 76(29) 58(40) 41 (53) 22(55) 14(57) 6(50) 2(60) 0(60) Docetaxel 101(0) 175(14) 141(47) 118(70) 95(91) 78(103) 36(119) 21(124) 6(126) 3(126) 0(126) Docetaxel 113(0) 102(9) 93(18) 83(28) 63(40) 50(48) 28(59) 20(60) 9(61) 4(61) 2(61) CL, confidence interval, CR complete response, HR, hazard ratio; OS, overall survival, PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease, SG, sacituzumab govitecan 2024 ASCO #ASCO24 PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation property of the author and ASCO Permission required or ITUM contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- [Slide 4] Overall Survival: Nonresponsive (SD/PD) to Last Anti-PD-(L)1-Containing Regimen, by Histology SG had similar OS improvement over docetaxel in both nonsquamous and squamous histology Nonsquamous Squamous 100 100 SG Docetaxel SG Docetaxel 90 (n = 142) (n = 145) 90 (n = 50) (n = 46) 80 Median, months 11.8 8.4 80 Median, months 10.7 7.9 (95% CI) (9.4-12.6) (7.0-11.2) (95% CI) (6.9-16.0) (5.3-10.2) 70 70 OS probability (%) HR (95% CI) 0.79 (0.59-1.07) HR (95% CI) 0.62 (0.36) 1.02) 60 60 50 46.7% os probability (%) 50 49.8% 40 40 30 37.3% 30 20 20 22.4% SG SG 10 10 Docetaxel Docetaxel 0 0 0 2 4 6 8 10 12 14 16 18 20 0 2 4 6 8 10 12 14 16 18 20 Patients still at risk, N (events) Time (months) Time (months) Patients still at risk, N (events) SG 142(0) 131(11) 111(30) 101(40) 88(52) 73(62) 38(71) 19(77) 7(78) 4(78) 0(78) SG 50(0) 44(5) 38(11) 34(14) 28(20) 25(22) 15(24) 7(28) 4(29) 4(29) 0(30) Docetaxel 145(0) 135(0) 109(35) 93(51) 74(68) 62(77) 30(87) 16(91) 5(92) 3(92) 0(92) Docetaxel 46(0) 40(5) 32(12) 25(19) 21(23) 16(26) 6(32) 5(33) 1(34) CI, confidence interval, HR, hazard ratio; OS, overall survival, PD, progressive disease; PD-(L)1, programmed death (ligand) 1; SD, stable disease; SG, sacituzumab govitecan. 024 ASCO #ASCO24 PRESENTED BY: Dr. Luis G, Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY INUAL MEETING Presentation 6 property of the author and ASCO Permission required or reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

[Slide 1] Target Drug Payload Linker DAR HER3 Patritumab-DXd Topoisomerase Inhibitor Cleavable 8 Potential in EGFRm post-Osi NAM Pending HERTHENA-LUNG 02 Biomarker selection not required EVOKE-01 vs Docetaxel TROP2 Sacituzumab govitecan Topoisomerase Inhibitor Cleavable 7.6 3365 Negative for OS Tropion-LUNG01 vs Docetaxel TROP2 Datopotamab-DXd Topoisomerase Inhibitor Cleavable 4 Negative for OS (Benefit PFS) Approved by the FDA AND EMA HER2* Trastuzumab-DXd Topoisomerase Inhibitor Cleavable 8 In HER2m NSCLC (2ND Line) Biomarker selection CARMEN-LC03 vs Docetaxel CEACAM5 Tusamitamab ravtansine Microtubule Inhibitor Cleavable 3.8 Negative for PFS/OS required P Potential in EGFRm post-Osi c-Met Telisotuzumab vedotin Microtubule Inhibitor Cleavable 3.1 Pending M22-142 in MET+ 2 c-Met ABBV-400 Topoisomerase Inhibitor Cleavable - --- [Slide 2] EVOKE-01: Global, Randomized, Open-Label, Phase 3 Study Key eligibility criteria Measurable stage IV NSCLC End points Sacituzumab ECOG PS 0-1 Primary govitecan Radiographic progression after platinum- 10 mg/kg on Days 1 and OS based and anti-PD-(L)1-containing 8 of 21-day cyclesd regimenᵃ N = 603 Secondary R In addition, patients with known AGAs PFS, ORR, DOR, and DCR must have received ≥ 1 approved TKIᵇ 1:1 by INV per RECIST v1.1 Docetaxel EGFR/ALK test required. Testing of other 75 mg/m² on Day 1 of Safety and tolerability AGAs recommended Previously treated stable brain 21-day cyclesd QoL using NSCLC-SAQ metastases were included Stratified by No prior treatment with Topo-1 inhibitors, Histology (squamous VS nonsquamous) Response to last anti-PD-(L)1-containing regimen (responsive [best response Trop-2-targeted therapies, or docetaxel CR/PR] VS nonresponsive [PD/SD]) Received prior targeted therapy for AGA (yes VS no) At data cutoff (29 November 2023), the study median follow-up was 12.7 months (range, 6.0-24.0) and availability of testing/approved targeted agent Unitil PD or unacceptable toxicity AGA, actionable genomic alteration; CR, complete response, DCR, disease control rate; DOR, duration of response, ECOG PS, Eastern *(Noo)adjuvant therapy counted if progression within 6 months of platinum treatment and while on maintenance with checkpoint inhibitor agent. if local approval exists for targeted therapy to that genomic alteration Based on Cooperative local SOC Oncology Group performance status; INV, investigator, NSCLC non-small cell lung cancer, NSCLC-SAQ, Non-small Cell Lung Cancer Symptom Assessment Questionnaire: ORR, objective response rate; OS, overall survival; PD, progressive disease, PD-(L)1, programmed death (ligand) 1; PFS, progression-free survival, PR, partial response, QoL, quality of tife; R, randomization; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease, SOC, standard of care, TKI, tyrosine kinase inhibitor, Topo-1, topoisomerase-1; Trop-2, trophoblast cell surface antigen 2. ASCO AMERICAN SOCIETY 2024 ASCO PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre CLINICAL ONCOLOG #ASCO24 KNOWLEDGE CONQUERS CANC ANNUAL MEETING Presentation a property of the euthor and ASCO Permission required for - contact permissions@asco.org --- [Slide 3] Primary End Point: Overall Survival (ITT) SG Docetaxel 100 (n . 299) (n . 304) 90 Median, months 11.1 (9.4-12.3) 9.8 (8.1-10.6) (95% CI) 80 HR (95% CI) 0.84 (0.68-1.04) 1-sided P-value 0.0534 70 12-month OS rate, % 46.59 36.72 os probability (%) 60 (95% CI) (40.45-52.50) (30.88-42.57) 1-sided P-value for significance was PS 0.0223 50 46.6% 40 30 36.7% 20 10 SG Docetaxel 0 0 2 4 6 8 10 12 14 16 18 20 Time (months) Patients still at risk, N (events) SG 299 (0) 275 (23) 234 (63) 212 (83) 175 (112) 140 (137) 76 (150) 40 (162) 17 (166) 10 (167) 0 (168) Docetaxel 304 (0) 277 (23) 234 (65) 201 (98) 158 (131) 128 (151) 64 (178) 41 (184) 15 (187) 7 (187) 2 (187) CL confidence interval, HR, hazard ratio; ITT, intent to-treat, OS, overall survival; SG, sacitumab govitecan. ASCO AMERICAN SOCIETY OF 2024 ASCO PRESENTED UT: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre CLINICAL ONCOLOGY #ASCO24 KNOWLEDGE CONQUERS CANCER ANNUAL MEETING Presentation - property of the euthor and ASCO Permission required for FROM contact permissions@asco.org --- [Slide 4] Overall Survival: Subgroup Analyses Subgroup Hazard ratio HR (95% CI) Overall (n = 603) 0.84 (0.68-1.04) Histology Squamous (n = 164) 0.83 (0.56-1.22) Nonsquamous (n = 439) 0.87 (0.68-1.11) Best response to last anti-PD-(L)1-containing regimen PD/SD (n = 383) 0.75 (0.58-0.97) CR/PR (n = 219) 1.09 (0.76-1.56) Received prior therapy for AGA No (n = 559) 0.89 (0.72-1.11) Yes (n = 44) 0.52 (0.22-1.23) Age group < 65 years (n = 297) 0.80 (0.59-1.08) > 65 years (n = 306) 0.90 (0.68-1.20) Baseline ECOG PS 0 (n = 190) 1.06 (0.70-1.60) 1 (n = 410) 0.81 (0.64-1.04) 0.125 0.25 0.5 1 2 4 8 AGA actionable genomic alteration, CI, confidence interval, CR, complete response, ECOG PS, Eastern Cooperative Oncology Group performance status, HR, hazard ratio; PD, progressive disease, PD-(L)1, programmed death (ligand) 1; PR, partial response, SD, stable disease 2024 ASCO #ASCO24 PRESENTED BY BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for Nust, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

[Slide 1] EVOKE-01: Global, Randomized, Open-Label, Phase 3 Study Key eligibility criteria Measurable stage IV NSCLC Sacituzumab End points ECOG PS 0-1 Primary govitecan Radiographic progression after platinum- 10 mg/kg on Days 1 and OS based and anti-PD-(L)1-containing N = 603 8 of 21-day cyclesd regimenᵃ Secondary In addition, patients with known AGAs R PFS, ORR, DOR, and DCR must have received ≥ 1 approved TKIb 1:1 by INV per RECIST v1.1 EGFR/ALK test required. Testing of other Docetaxel AGAs recommended© 75 mg/m² on Day 1 of Safety and tolerability Previously treated stable brain 21-day cyclesᵈ QoL using NSCLC-SAQ metastases were included Stratified by No prior treatment with Topo-1 inhibitors, Histology (squamous VS nonsquamous) Trop-2-targeted therapies, or docetaxel Response to last anti-PD-(L)1-containing regimen (responsive [best response CR/PR] VS nonresponsive [PD/SD]) Received prior targeted therapy for AGA (yes VS no) At data cutoff (29 November 2023), the study median follow-up was 12.7 months (range, 6.0-24.0) (Neo)adjuvant therapy counted if progression within 6 months of platinum treatment and while on maintenance with checkpoint inhibitor agent. off local approval exists for targeted therapy to that genomic alteration 'Based on local SOC and availability of testing/approved targeted agent Until PD or unacceptable toxicity. AGA, actionable genomic alteration; CR, complete response, DCR, disease control rate; DOR, duration of response, ECOG PS, Eastern Cooperative Oncology Group performance status, INV. investigator, NSCLC. non-small cell lung cancer, NSCLC-SAQ Non-small Cell Lung Cancer Symptom Assessment Questionnaire; ORR, objective response rate; OS, overall survival; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PFS, progression-free survival PR, partial response; QoL. quality of life; R, randomization; RECIST v1.1. Response Evaluation Criteria in Solid Tumors version 1.1; SD, stable disease; SOC, standard of care; TKI, tyrosine kinase inhibitor; Topo-1, topoisomerase-1; Trop-2. trophoblast cell surface antigen 2. 2024 ASCO #ASCO24 PRESENTED BY Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- [Slide 2] Primary End Point: Overall Survival (ITT) SG Docetaxel 100 (n = 299) (n = 304) 90 Median, months (95% CI) 11.1 (9.4-12.3) 9.8 (8.1-10.6) 80 HR (95% CI) 0.84 (0.68-1.04) 1-sided P-value 0.0534 70 12-month OS rate, % 46.59 36.72 os probability (%) 60 (95% CI) (40.45-52.50) (30.88-42.57) 1-sided P-value for significance was P â 0.0223 50 46.6% 40 30 36.7% 20 10 SG Docetaxel 0 0 2 4 6 8 10 12 14 16 18 20 Patients still at risk, N (events) Time (months) SG 299 (0) 275 (23) 234 (63) 212 (83) 175 (112) 140 (137) 76 (150) 40 (162) 17 (166) 10 (167) 0 (168) Docetaxel 304 (0) 277 (23) 234 (65) 201 (98) 158 (131) 128 (151) 64 (178) 41 (184) 15 (187) 7 (187) 2 (187) CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat, OS, overall survival SG, sacituzumab govitecan 2024 ASCO #ASCO24 PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- [Slide 3] Overall Survival: Subgroup Analyses Subgroup Hazard ratio HR (95% CI) Overall (n = 603) 0.84 (0.68-1.04) Histology Squamous (n = 164) 0.83 (0.56-1.22) Nonsquamous (n = 439) 0.87 (0.68-1.11) Best response to last anti-PD-(L)1-containing regimen PD/SD (n = 383) 0.75 (0.58-0.97) CR/PR (n = 219) 1.09 (0.76-1.56) Received prior therapy for AGA No (n = 559) 0.89 (0.72-1.11) Yes (n = 44) 0.52 (0.22-1.23) Age group < 65 years (n = 297) 0.80 (0.59-1.08) ≥ 65 years (n = 306) 0.90 (0.68-1.20) Baseline ECOG PS 0 (n = 190) 1.06 (0.70-1.60) 1 (n = 410) 0.81 (0.64-1.04) 0.125 0.25 0.5 1 2 4 8 AGA actionable genomic alteration; CI, confidence interval; CR, complete response, ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PD, progressive disease; PD-(L)1, programmed death (ligand) 1: PR, partial response, SD, stable disease 2024 ASCO #ASCO24 PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

[Slide 1] 2:45 PM-5:45 PM Oral Abstract Session Lung Cancer-Non-Sma Cell Metastatic Location: Arie Crown Theater Ticiana Leal, MD-Chair Winship Cancer Institute at Emory University Sarah B. Goldberg, MD-Chair Yale School of Medicine 2:45 PM Abstract LBA8500: Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non- small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. First Author: Luis G. Paz-Ares, PhD 2:57 PM Abstract 8501: ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. First Author: David Planchard, MD, PhD 3:09 PM Abstract 8502: Sacituzumab tirumotecan (SKB264/ MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. First Author: Wenfeng Fang, MD, PhD 3:21 PM Egbert F. Smit, MD, PhD Leiden University Medical Centre Discussion of Abstract(s) LBA8500-8502: Managing Expectations With Antibody-Drug Conjugates in Non- Small Cell Lung Cancer 3:33 PM Panel Question and Answer

[Slide 1] Primary End Point: Overall Survival (ITT) SG Docetaxel 100 (n = 299) (n = 304) Median, months 90 11.1 (9.4-12.3) 9.8 (8.1-10.6) (95% CI) HR (95% CI) 0.84 (0.68-1.04) 80 1-sided P-value 0.0534 70 12-month os rate, % 46.59 36.72 (95% CI) (40.45-52.50) (30.88-42.57) 60 1-sided P-value for significance was P S 0.0223 46.6% 50 40 30 36.7% 20 10 SG Docetaxel 0 8 10 12 14 16 18 20 0 2 4 6 Time (months) Patients still at risk, N (events) SG 299 (0) 275 (23) 234 (63) 212 (83) 175 (112) 140 (137) 76 (150) 40 (162) 17 (166) 10 (167) 0 (168) 304 (0) 277 (23) 234 (65) 201 (98) 158 (131) 128 (151) 64 (178) 41 (184) 15 (187) 7 (187) 2 (187) Docetaxel CI, confidence interval HR, hazard ratio; ITT. intent-to-treat OS, overall survival SG, sacituzumab govitecan ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO KNOWLEDGE CONQUERS CANCER 2024 #ASCO24 Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org ANNUAL MEETING --- [Slide 2] Secondary End Points (ITT) Progression-free Survival Objective Response Rate 100 SG Docetaxel SG Docetaxel 90 (n = 299) (n = 304) (n = 299) (n = 304) 80 Median, months 4.1 (3.0-4.4) 3.9 (3.1-4.2) ORR, % (95% CI) 13.7 (10.0-18.1) 18.1 (13.9-22.9) (95% CI) 70 DCR, % (95% CI) 67.6 (61.9-72.8) 67.1 (61.5-72.4) HR 0.92 (0.77-1.11) (95% CI) Median DOR, months 60 (95% CI) 6.7 (4.4-9.8) 5.8 (4.1-8.3) DOR rate at 6 months, % 50 (95% CI) 52.5 (35.6-66.9) 46.5 (31.9-59.8) 40 30 20 10 SG Docetaxel 0 0 2 4 6 8 10 12 14 16 18 20 Patients still at risk, N (events) Time (months) SG 299 (0) 201 (84) 143 (139) 89 (187) 66 (208) 32 (228) 15 (235) 6 (238) 2 (238) 0 (238) Docetaxel 304 (0) 190 (81) 124 (138) 72 (181) 46 (203) 22 (220) 10 (224) 5 (226) 2 (227) 2 (227) 2 (227) By INV assessment CI, confidence interval; DCR disease control rate; DOR duration of response HR hazard ratio; INV. investigator, ITT. intent-to-treat ORR objective response rate; PFS, progression-free survival; SG, sacituzumab govitecan 2024 ASCO PRESENTED BY: Dr. Luis G. Paz-Ares, Hospital Universitario 12 de Octubre ASCO AMERICAN SOCIETY OF #ASCO24 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse contact org KNOWLEDGE CONQUERS CANCER